GlassScriptPhysician profile
Jamela Davis
NPI 1164068243
$4,005.36
in general payments reported to CMS, 2019-2025
25 companies · $971 in 2025
The $971 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,021 · 2022: $561 · 2023: $585 · 2024: $868 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,276.86 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $671.63 | 2021-2025 | |
| Abbvie INC. | $458.11 | 2023-2025 | |
| Nevro Corp. | $377.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.48 | 2022 | |
| Collegium Pharmaceutical, INC. | $111.26 | 2021 | |
| Stimwave Technologies Incorporated | $100.62 | 2021 | |
| Lundbeck LLC | $92.76 | 2023 | Vyepti |
| Medtronic, INC. | $85.74 | 2024 | Strata, Mazor X System |
| Axsome Therapeutics, INC. | $56.45 | 2025 | Symbravo |
| Theragen, INC. | $51.39 | 2022 | |
| Virtus Pharmaceuticals LLC | $42.42 | 2021 | |
| Scilex Pharmaceuticals INC. | $28.30 | 2021 | |
| Biodelivery Sciences International, INC. | $26.01 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $25.39 | 2021 | |
| Lilly USA, LLC | $24.72 | 2022 | |
| Almatica Pharma LLC | $23.32 | 2021 | |
| Arteriocyte Medical Systems, INC. | $21.83 | 2022 | |
| Grt US Holding, INC. | $17.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.60 | 2021 | |
| Amgen INC. | $15.41 | 2021 | |
| Pacira Therapeutics, INC. | $15.29 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.62 | 2025 | Nuzyra, Xhance |
| Horizon Therapeutics Plc | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamela Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.